Table 1.

Clinicopathological Parameters of Patients with High or Low CTSZ Level from TCGA Cohorts

Characteristic	Low Expression of CTSZ (n=269)	High Expression of CTSZ (n=270)	p
T stage, n (%)			0.036
T1	151 (28%)	127 (23.6%)
T2	36 (6.7%)	35 (6.5%)
T3	80 (14.8%)	99 (18.4%)
T4	2 (0.4%)	9 (1.7%)
N stage, n (%)			0.279
N0	117 (45.5%)	124 (48.2%)
N1	5 (1.9%)	11 (4.3%)
M stage, n (%)			0.003
M0	224 (44.3%)	204 (40.3%)
M1	26 (5.1%)	52 (10.3%)
Pathologic stage, n (%)			0.010
Stage I	149 (27.8%)	123 (22.9%)
Stage II	32 (6%)	27 (5%)
Stage III	59 (11%)	64 (11.9%)
Stage IV	28 (5.2%)	54 (10.1%)
Gender, n (%)			< 0.001
Female	113 (21%)	73 (13.5%)
Male	156 (28.9%)	197 (36.5%)
Race, n (%)			0.432
Asian	2 (0.4%)	6 (1.1%)
Black or African American	28 (5.3%)	29 (5.5%)
White	235 (44.2%)	232 (43.6%)
OS event, n (%)			0.103
Alive	192 (35.6%)	174 (32.3%)
Dead	77 (14.3%)	96 (17.8%)
Age, mean ± SD	61.88 ± 11.56	59.38 ± 12.49	0.016